- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | Red Light Holland Corp.: Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs | 308 | Newsfile | Toronto, Ontario--(Newsfile Corp. - April 23, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth and sale of functional... ► Artikel lesen | |
| 19.04. | Pharmala Biotech Holdings Inc: Pharmala closes $750,000 private placement | 2 | Stockwatch | ||
| 19.04. | PharmAla Biotech: PharmAla Closes Private Placement and Concurrent Debt Settlement | 703 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, April 19, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research... ► Artikel lesen | |
| 12.04. | Pharmala Biotech Holdings Inc: Red Light Holland ships psilocybin truffles to CCrest | 1 | Stockwatch | ||
| 10.04. | Pharmala Biotech Holdings Inc: Pharmala Biotech arranges $750,000 private placement | 1 | Stockwatch | ||
| 10.04. | PharmAla announces private placement of up to $750,000 | 1 | Seeking Alpha | ||
| 10.04. | PharmAla Biotech: PharmAla Announces Private Placement and Concurrent Debt Settlement | 1 | GlobeNewswire (USA) | ||
| 05.04. | Pharmala Biotech Holdings Inc: Pharmala JV begins GMP production of LaNeo in Australia | 1 | Stockwatch | ||
| 05.04. | PharmAla Biotech: Cortexa Commences Manufacturing GMP LaNeo MDMA in Australia | 200 | GlobeNewswire (Europe) | TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 28.03. | PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development | 2 | Benzinga.com | ||
| 27.03. | Pharmala Biotech Holdings Inc: Pharmala receives allowance for ALA-002 from USPTO | 1 | Stockwatch | ||
| 27.03. | PharmAla Biotech: Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office | 216 | GlobeNewswire (Europe) | TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 26.03. | Pharmala Biotech Holdings Inc: Pharmala Biotech to provide LaNeo MDMA to Numinus | 2 | Stockwatch | ||
| 26.03. | Numinus Wellness Inc: Pharmala Biotech to provide LaNeo MDMA to Numinus | 4 | Stockwatch | ||
| 26.03. | PharmAla biotech signs sale agreement with Numinus Wellness | 2 | Seeking Alpha | ||
| 20.03. | Pharmala Biotech Holdings Inc: Pharmala Biotech Holdings to resume at 8 a.m. PT | 1 | Stockwatch | ||
| 20.03. | Pharmala Biotech Holdings Inc: Pharmala receives USPTO allowance for P-1 molecule | 1 | Stockwatch | ||
| 20.03. | PharmAla Biotech: Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office | 1 | GlobeNewswire (USA) | ||
| 20.03. | Pharmala Biotech Holdings Inc: Pharmala Biotech Holdings halted at 6:36 a.m. PT | 1 | Stockwatch | ||
| 18.03. | Pharmala Biotech Holdings Inc: Pharmala JV supplies first psilocybin under TGA scheme | 1 | Stockwatch |
Seite:
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,840 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen | |
| MORPHOSYS | 66,05 | -0,23 % | Flut an Quartalszahlen: So reagiert der DAX - Außerdem im Fokus: Adidas und MorphoSys | Am Dienstag sind eine ganze Fülle von wichtigen Quartalszahlen präsentiert worden. Wie reagiert der deutsche Leitindex darauf? Außerdem im Fokus: Adidas und MorphoSys. Die Anleger am deutschen Aktienmarkt... ► Artikel lesen | |
| ARVINAS | 32,480 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,740 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,310 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| EVOTEC | 9,940 | +2,05 % | Evotec: War dieser Crash berechtigt? | Auf den ersten Blick wirkten die Ergebnisse des Vorjahres, die Evotec am Mittwochmorgen vorlegte, zwar nicht gerade gut, aber sie hätten nie und nimmer die Basis für einen Crash von 32 Prozent sein... ► Artikel lesen | |
| COGENT BIOSCIENCES | 6,910 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor | WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 28,100 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| QIAGEN | 39,875 | +2,03 % | DAX-Check LIVE: Bilanzenflut - Adidas, Covestro, Mercedes-Benz, MTU, Qiagen, Volkswagen Vz., Vonovia | Der DAX ist gestern nach anfänglichen Gewinnen ins Minus gerutscht. Am Ende des Tages ging er mit einem Verlust von 0,24 Prozent aus dem Handel. Worauf es jetzt für den DAX ankommt, erläutert Thomas... ► Artikel lesen | |
| NUVALENT | 70,65 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 17,680 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| ARCELLX | 52,16 | 0,00 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| RELAY THERAPEUTICS | 6,660 | +2,15 % | Relay Therapeutics, Inc.: Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024 | ||
| CYTOMX THERAPEUTICS | 4,094 | +167,23 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 19,010 | 0,00 % | Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies | Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten... ► Artikel lesen |
PHARMALA BIOTECH HOLDINGS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
